File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1155/2019/2673543
- Scopus: eid_2-s2.0-85064239955
- WOS: WOS:000461630900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer
Title | Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer |
---|---|
Authors | |
Issue Date | 2019 |
Publisher | Hindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/dm/ |
Citation | Disease Markers, 2019, v. 2019, p. 2673543:1-2673543:8 How to Cite? |
Abstract | Colorectal cancer (CRC) is a leading cancer globally; therefore, early diagnosis and surveillance of this cancer are of paramount importance. Current methods of CRC diagnosis rely heavily on endoscopy or radiological imaging. Noninvasive tests including serum detection of the carcinoembryonic antigen (CEA) and faecal occult blood testing (FOBT) are associated with low sensitivity and specificity, especially at early stages. DNA methylation biomarkers have recently been found to have higher accuracy in CRC detection and enhanced prediction of prognosis and chemotherapy response. The most widely studied biomarker in CRC is methylated septin 9 (SEPT9), which is the only FDA-approved methylation-based biomarker for CRC. Apart from SEPT9, other methylated biomarkers including tachykinin-1 (TAC1), somatostatin (SST), and runt-related transcription factor 3 (RUNX3) have been shown to effectively detect CRC in a multitude of sample types. This review will discuss the performances of various methylated biomarkers used for CRC diagnosis and monitoring, when used alone or in combination. |
Persistent Identifier | http://hdl.handle.net/10722/269343 |
ISSN | 2021 Impact Factor: 3.464 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ma, Z | - |
dc.contributor.author | Williams, M | - |
dc.contributor.author | Cheng, YY | - |
dc.contributor.author | Leung, WK | - |
dc.date.accessioned | 2019-04-24T08:05:45Z | - |
dc.date.available | 2019-04-24T08:05:45Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Disease Markers, 2019, v. 2019, p. 2673543:1-2673543:8 | - |
dc.identifier.issn | 0278-0240 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269343 | - |
dc.description.abstract | Colorectal cancer (CRC) is a leading cancer globally; therefore, early diagnosis and surveillance of this cancer are of paramount importance. Current methods of CRC diagnosis rely heavily on endoscopy or radiological imaging. Noninvasive tests including serum detection of the carcinoembryonic antigen (CEA) and faecal occult blood testing (FOBT) are associated with low sensitivity and specificity, especially at early stages. DNA methylation biomarkers have recently been found to have higher accuracy in CRC detection and enhanced prediction of prognosis and chemotherapy response. The most widely studied biomarker in CRC is methylated septin 9 (SEPT9), which is the only FDA-approved methylation-based biomarker for CRC. Apart from SEPT9, other methylated biomarkers including tachykinin-1 (TAC1), somatostatin (SST), and runt-related transcription factor 3 (RUNX3) have been shown to effectively detect CRC in a multitude of sample types. This review will discuss the performances of various methylated biomarkers used for CRC diagnosis and monitoring, when used alone or in combination. | - |
dc.language | eng | - |
dc.publisher | Hindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/dm/ | - |
dc.relation.ispartof | Disease Markers | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer | - |
dc.type | Article | - |
dc.identifier.email | Leung, WK: waikleung@hku.hk | - |
dc.identifier.authority | Leung, WK=rp01479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1155/2019/2673543 | - |
dc.identifier.scopus | eid_2-s2.0-85064239955 | - |
dc.identifier.hkuros | 297528 | - |
dc.identifier.volume | 2019 | - |
dc.identifier.spage | 2673543:1 | - |
dc.identifier.epage | 2673543:8 | - |
dc.identifier.isi | WOS:000461630900001 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0278-0240 | - |